{"id":"hsk31858-tablet","safety":{"commonSideEffects":[{"rate":null,"effect":"Hyperphosphatemia"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"HSK31858 targets FGFR kinase activity to inhibit downstream proliferation and survival pathways in FGFR-dependent tumors. By selectively blocking FGFR signaling, the drug aims to suppress tumor growth in cancers driven by FGFR alterations, including amplifications, mutations, and fusions.","oneSentence":"HSK31858 is a selective inhibitor of fibroblast growth factor receptor (FGFR) that blocks aberrant FGFR signaling in cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:46:09.993Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"FGFR-driven solid tumors (phase 3 development)"}]},"trialDetails":[{"nctId":"NCT07134478","phase":"PHASE1","title":"Clinical Study to Evaluate the Effect of Rifampicin on the Pharmacokinetics of HSK31858 in Healthy Subjects","status":"ACTIVE_NOT_RECRUITING","sponsor":"Haisco Pharmaceutical Group Co., Ltd.","startDate":"2024-10-28","conditions":"Healthy Subjects","enrollment":24},{"nctId":"NCT07134465","phase":"PHASE1","title":"Clinical Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of HSK31858 in Healthy Subjects","status":"ENROLLING_BY_INVITATION","sponsor":"Haisco Pharmaceutical Group Co., Ltd.","startDate":"2025-08-11","conditions":"Healthy Subjects","enrollment":24},{"nctId":"NCT06820749","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of HSK31858 Tablets in Patients with Airway Mucus Hypersecretion","status":"ENROLLING_BY_INVITATION","sponsor":"Haisco Pharmaceutical Group Co., Ltd.","startDate":"2024-12-10","conditions":"Asthma Bronchiale, Bronchiectasis, Chronic Obstructive Pulmonary Disease (COPD)","enrollment":309},{"nctId":"NCT06637254","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of HSK31858 Tablets in Patients with Bronchial Asthma","status":"ENROLLING_BY_INVITATION","sponsor":"Haisco Pharmaceutical Group Co., Ltd.","startDate":"2024-10-22","conditions":"Bronchial Asthma","enrollment":219},{"nctId":"NCT06660992","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of HSK31858 in Participants With Non-Cystic Fibrosis Bronchiectasis","status":"RECRUITING","sponsor":"Haisco Pharmaceutical Group Co., Ltd.","startDate":"2024-09-30","conditions":"Non-cystic Fibrosis Bronchiectasis","enrollment":669},{"nctId":"NCT05663593","phase":"PHASE1","title":"Safety, Tolerability,PK/PD, Food Effect of Single and Multiple Ascending Doses of HSK31858 in Healthy Volunteers","status":"COMPLETED","sponsor":"Haisco Pharmaceutical Group Co., Ltd.","startDate":"2022-02-23","conditions":"Healthy Volunteers","enrollment":74},{"nctId":"NCT05023525","phase":"PHASE1","title":"A Study of Safety, Tolerability, and Pharmacokinetics of Single Ascending Dosed of HSK31858 in Healthy Volunteers","status":"COMPLETED","sponsor":"Haisco Pharmaceutical Group Co., Ltd.","startDate":"2021-10-28","conditions":"Healthy","enrollment":32}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"HSK31858, tablet","genericName":"HSK31858, tablet","companyName":"Haisco Pharmaceutical Group Co., Ltd.","companyId":"haisco-pharmaceutical-group-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"HSK31858 is a selective inhibitor of fibroblast growth factor receptor (FGFR) that blocks aberrant FGFR signaling in cancer cells. Used for FGFR-driven solid tumors (phase 3 development).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}